Kyverna therapeutics provides business update and reports second quarter 2025 financial results

Topline data for registrational phase 2 trial of kyv-101 in stiff person syndrome (sps) and bla submission anticipated in 1h 2026

KYTX Ratings Summary

KYTX Quant Ranking